A5004936309- Colorectal Cancer Treatments and Studies
- Sarcoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Cancer, Lipids, and Metabolism
- Colorectal and Anal Carcinomas
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer and Skin Lesions
- Ferroptosis and cancer prognosis
- Oral and Maxillofacial Pathology
- Gastrointestinal Tumor Research and Treatment
- Bone Tumor Diagnosis and Treatments
- Cancer, Hypoxia, and Metabolism
- Angiogenesis and VEGF in Cancer
- Soft tissue tumor case studies
Hospital de Sant Pau
2015-2025
Institut de Recerca Sant Pau
2024
Universitat Autònoma de Barcelona
2011-2023
Royal Marsden NHS Foundation Trust
2018
Royal Marsden Hospital
2018
University of Southern California
2014-2017
USC Norris Comprehensive Cancer Center
2014-2015
PharmacoGenetics (China)
2014
Weatherford College
2014
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. Epigenetic gene silencing is increasingly being recognized factor conferring distinct tumoral drug sensitivity, so we comprehensive DNA methylation microarray platform interrogate widely characterized NCI60 panel of human cell...
Background: The clinical outcome of inoperable sarcoma patients treated with LATTICE (LRT) is limited and therefore the objective our study was to report treatment response, overall survival (OS), local-recurrence free (LRFS) toxicity. Methods: This retrospective observational includes 15 histologically proven non-extremity no options or response systemic therapy, at institution between 2020 2024. were a combination LRT normo- hypo-fractionated external beam radiotherapy. Treatment evaluated...
Infusional fluorouracil/leucovorin (FU/LV) plus irinotecan (FOLFIRI) is one of the standard first-line options for patients with metastatic colorectal cancer (mCRC). Irinotecan converted into 7-ethyl-10-hydroxycamptothecin (SN-38) by a carboxylsterase and metabolised through uridine diphosphate glucuronosyl transferase (UGT1A1). The UGT1A1*28 allele has been associated risk developing severe toxicities. present trial was designed to define maximum tolerated dose according UGT1A1 genotype....
The Salvador-Warts-Hippo pathway controls cell fate and tissue growth. main function of the Hippo is to prevent YAP TAZ translocation nucleus where they induce transcription genes involved in proliferation, survival, stem maintenance. signaling is, thus, a complex tumor suppressor, its deregulation key feature many cancers. Recent mounting evidence suggests that overexpression components can be useful prognostic biomarkers. Moreover, appears intimately linked some most important pathways...
Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, in later stages the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after onset imatinib resistance. Thus, circulating (ct)DNA determination expected to be an informative non-invasive dynamic biomarker GIST patients.We performed amplicon-based next-generation sequencing (NGS) across 60 clinically relevant genes 37 plasma samples from 18...
Objective Although KRAS mutation status has been identified as a strong predictor of response to anti-epidermal growth factor receptor (EGFR) therapies, not all wild-type patients respond. The lethal-7 (let-7) family microRNAs regulates activity. A functional polymorphism (rs61764370) described in the let-7 complementary site (LCS6). We hypothesized possible association between this LCS6 and anti-EGFR treatments BRAF metastatic colorectal cancer (mCRC). Materials methods studied with 100...
11502 Background: The immunogenic death caused by certain chemotherapy agents consists of molecular changes in tumor dying cells that stimulate immunogenicity and enhance antitumor effects. Doxorubicin is one validated drug related to death, mainly through calreticulin membrane translocation elicits signals as phagocytosis dendritic cells. Doxorubicin+pembrolizumab was explored a phase I/II trial treating patients with metastatic/unresectable sarcomas, achieving 22% PR, 59% SD, 19% PD, mPFS...
Patients harbouring the UGT1A1*28/*28 genotype are at risk of severe toxicity with standard irinotecan dose. However, this dose is considerably lower than that can be tolerated by UGT1A1*1/*1 and *1/*28 patients. This randomised phase II trial evaluated efficacy safety FOLFIRI regimen high-dose (HD-FOLFIRI) in metastatic colorectal cancer patients.Eighty-two patients or were to receive HD-FOLFIRI versus FOLFIRI. excluded. In experimental group, was 300 mg/m2 for 260 control 180 mg/m2. We...
3064 Background: ICIs are associated with irAEs. We describe the incidence of irAEs in patients solid tumors receiving and its correlation efficacy. Methods: retrospectively analyzed all our center. IrAEs were graded according CTCAE v4.0. Kaplan Meier log-rank tests used to evaluate progression-free (PFS) overall survivals (OS). Analyses performed using SPSS v24 package. Results: From March 2014 January 2018, 178 received ICIs. Median age was 64.1 [33-88] years, 72% male. Most frequent lung...
PURPOSE Doxorubicin, alongside a select group of cytotoxic agents, is capable inducing an adaptive immune response via well-established peculiar type tumor cell death called immunogenic (ICD). We hypothesize that combining doxorubicin and dacarbazine with nivolumab may enhance therapeutic efficacy by exerting synergy in the ICD circuit. hereby present phase Ib trial this combination. PATIENTS AND METHODS Patients advanced leiomyosarcoma anthracycline-naïve were eligible. The initial dose...
11514 Background: It was hypothesized that anthracycline-based chemotherapy plus anti-PD1 (nivolumab) could enhance the activity of upfront in advanced UPS, based on a double-hit immunogenic cell death circuit. This peculiar tumor eventually activates an adaptive immune response through particular molecular changes dying cells and microenvironment, triggered by specific drugs such as anthracyclines. We previously reported phase Ib trial leiomyosarcoma patients with combination doxorubicin,...
11513 Background: Extraskeletal myxoid chondrosarcoma (EMC) is an ultra-rare sarcoma, with low sensitivity to classic chemotherapy. A previous clinical trial led by our groups showed the activity of antiangiogenics (specifically pazopanib) in patients (pts) advanced ECM. As IMMUNOSARC I master-trial exploring sunitinib (S) plus nivolumab (N) sarcoma detected signal ECM pts, a specific cohort was designed as phase II within (NCT03277924). Methods: Adult pts advanced, progressing, measurable...
11540 Background: Pazopanib was shown to be active in advanced Solitary Fibrous Tumor (SFT), with 58% and 51% of the typical malignant/ dedifferentiated SFT patients, achieving an objective response by Choi criteria, international phase II clinical trial led our team. Nonetheless, predictive biomarkers pazopanib efficacy represent a unmet need, support rational selection this drug histology. We presented here transcriptomic-based signature for SFT. Methods: Patients enrolled GEIS 32...
Abstract Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for successful rational development targeted therapies in cancer. The introduction tyrosine kinase inhibitors with activity against KIT/PDGFRA both localized advanced stages has remarkably improved survival disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by conjoint effort Spanish Society Medical Oncology (SEOM)...
Severe irinotecan-induced toxicity is associated with UGT1A1 polymorphisms. However, some patients develop side-effects despite harbouring a normal genotype. As CYP3A4 also an irinotecan-metabolizing enzyme, our study aimed to elucidate the influence of CYP3A4*20 loss-of-function allele in profile these patients. Three-hundred and eight metastatic colorectal cancer treated irinotecan-containing chemotherapy were studied. The presence CYP3A4*20, UGT1A1*37 UGT1A1*28 alleles was tested....
11522 Background: Herein, we present the results of cohort on advanced bone sarcoma patients phase II part IMMUNOSARC study (NCT03277924), a European multicentre I-II trial aimed at investigating activity combination sunitinib (SU) and nivolumab (NI) in selected subtypes. Methods: Adult, pre-treated, progressing patients, ECOG 0-1, with diagnosis osteosarcoma, high-grade sarcoma, Ewing chondrosarcoma or dedifferentiated were eligible. SU 37.5 mg/day as induction was given days 1-14 then...
Irinotecan is widely used in the treatment of metastatic colorectal cancer (mCRC) despite its severe toxicities. Toxicity often associated with UGT1A1*28/*28 genotype. An explanation for idiopathic toxicity beyond UGT1A1 biomarker, however, remains a major concern clinicians. One main irinotecan transporters P-glycoprotein (P-gp), which hepatic efflux pump encoded by ABCB1. P-gp involved biliary excretion and active metabolite SN-38. We aimed to assess whether functional variants ABCB1 also...